Unknown

Dataset Information

0

A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy.


ABSTRACT: BACKGROUND:Adoptive transfer of genetically engineered T-cells to express antigen-specific T-cell receptor (TCR) is a feasible and effective therapeutic approach for numerous types of cancers, including Epstein-Barr virus (EBV)-associated malignancies. Here, we describe a TCR gene transfer regimen to rapidly and reliably generate T-cells specific to EBV-encoded latent membrane protein-1 (LMP1), which is a potential target for T-cell-based immunotherapy. METHODS:A novel TCR specific to LMP1 (LMP1-TCR) was isolated from HLA-A*0201 transgenic mice that were immunised with the minimal epitope LMP1166 (TLLVDLLWL), and LMP1-TCR-transduced peripheral blood lymphocytes were evaluated for functional specificities. RESULTS:Both human CD8 and CD4 T-cells expressing the LMP1-TCR provoked high levels of cytokine secretion and cytolytic activity towards peptide-pulsed and LMP1-expressing tumour cells. Notably, recognition of these T-cells to peptide-pulsed cells was maintained at low concentration of peptide, implying that the LMP1-TCR has high avidity. Infusion of these engineered T-cells revealed remarkable therapeutic effects and inhibition of tumour growth in a preclinical xenogeneic model. We observed explosive ex vivo proliferation of functional TCR-transduced T-cells with artificial antigen-presenting cells that express co-stimulatory molecules CD80 and 4-1BBL. CONCLUSIONS:These data suggest that the novel TCR-targeting LMP1 might allow the potential design of T-cell-based immunotherapeutic strategies against EBV-positive malignancies.

SUBMITTER: Cho HI 

PROVIDER: S-EPMC5830600 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy.

Cho Hyun-Il HI   Kim Un-Hee UH   Shin A-Ri AR   Won Ji-Na JN   Lee Hyun-Joo HJ   Sohn Hyun-Jung HJ   Kim Tai-Gyu TG  

British journal of cancer 20180123 4


<h4>Background</h4>Adoptive transfer of genetically engineered T-cells to express antigen-specific T-cell receptor (TCR) is a feasible and effective therapeutic approach for numerous types of cancers, including Epstein-Barr virus (EBV)-associated malignancies. Here, we describe a TCR gene transfer regimen to rapidly and reliably generate T-cells specific to EBV-encoded latent membrane protein-1 (LMP1), which is a potential target for T-cell-based immunotherapy.<h4>Methods</h4>A novel TCR specifi  ...[more]

Similar Datasets

| S-EPMC3432040 | biostudies-literature
2008-01-03 | E-GEOD-10057 | biostudies-arrayexpress
2008-01-04 | GSE10057 | GEO
| S-EPMC1642148 | biostudies-literature
| S-EPMC10376452 | biostudies-literature
| S-EPMC5362222 | biostudies-literature
| S-EPMC5724866 | biostudies-literature
| S-EPMC5625482 | biostudies-literature
| S-EPMC5599068 | biostudies-literature
| S-EPMC8019199 | biostudies-literature